Opendata, web and dolomites

CADISS SIGNED

A medical device for the selective dissection of pathological tissues and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CADISS project word cloud

Explore the words cloud of the CADISS project. It provides you a very rough idea of what is the project "CADISS" about.

repair    international    mechanical    selective    money    damage    23    tissue    expansion    10    tools    force    space    tissues    plane    involve    minimizing    pioneer    weakens    market    surgeon       grow    least    critical    pathological    complications    incidence    damages    separated    cutting    hospital    difficulties    risk    cadiss    treatable    tearing    countries    optimal    rooms    relapse    launch    surgeries    surrounding    2025    whereby    damaged    dissection    chemical    consisting    undergo    combines    million    found    sub    replace    period    reducing    hospitals    company    despite    organ    people    reaching    risks    anesthesia    healthy    valued    30    save    surgical    diseased    assisted    patients    either    surgery    amounting    carefully    size    disease    thereby    remove    150    dissecting    drug    optimize    adhesion    time    9m    separation    true    attributed    burden    auxin    global    cagr    relying    saves    topical    revolutionary    shorter    chemically    billion    health    2016    occupation    mesna    revenues    cleavage    surgically   

Project "CADISS" data sheet

The following table provides information about the project.

Coordinator
AUXIN SURGERY 

Organization address
address: RUE LOUIS DE GEER 6
city: LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AUXIN SURGERY BE (LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Surgery is the art of dissecting tissues in order to repair, remove, or replace a diseased or damaged organ. 30% of the global burden of disease can be attributed to surgically treatable conditions. More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. These procedures together have an incidence of 150/100.000 people, amounting for 2 million surgeries per year in developed countries. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting that can damage tissues. Auxin Surgery, a pioneer in novel dissection methods, has found a revolutionary system, CADISS, that combines mechanical force with the topical application of a chemical drug, Mesna that weakens adhesion between tissues thereby facilitating the dissection steps and minimizing the damages to health tissues. CADISS saves time, therefore patients need to undergo anesthesia for shorter period, thereby reducing the risks of complications. Moreover, hospitals save money on the usage of operating rooms and hospital personnel and can optimize the occupation of hospital space. The global general surgery devices market size was valued at over €10 billion in 2016 and is expected to grow at a CAGR of 8.5% by 2025. Chemically assisted dissection can be useful in most surgical procedures consisting in separation of two tissues along a cleavage plane and when at least one of these conditions is true: 1) the risk of relapse is present 2) the risk of side-effects through damage of healthy tissue is present or 3) the risk of facing difficulties for the surgeon is present. CADISS will bring our company to international expansion and growth reaching €23.9M in revenues 3 years after market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CADISS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CADISS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More